CFO Thacker said, “excluding subscribers generated from the highest level of promotions in Q2 '23, our year-over-year ...
Oncolytics Biotech® Inc. ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal ("GI") Tumor Scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback